Tuesday, October 21, 2014

Analysts launch coverage of Tokai Pharma

Analysts launch coverage of Tokai Pharma

October 13, 2014 by · Leave a Comment 

Tweet Analysts at William Blair, Stifel and Janney Capital Markets initiated coverage of Tokai Pharmaceuticals (NASDAQ:TKAI), saying its lead asset, galeterone, represents a first-in-class and best-in-class, selective and multi-targeted small molecule that should offer advantages over existing prostate cancer therapies. Analyst Katherine Xu started Tokai at “outperform” with a $44 price target. Shares of Tokai […]

Finding the origins of cancer with Rosetta Genomics

Finding the origins of cancer with Rosetta Genomics

August 26, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=z8RTk67NNWg’]

Tweet Taking its name from the Rosetta Stone, which paved the way to decipher ancient Egyptian hieroglyphics, Rosetta Genomics (NASDAQ:ROSG) is unlocking the relevance of microRNA within the human genome to develop next generation diagnostic tests for personalized medicine. “MicroRNAs are master gene regulators of almost every activity in the cell, and when something goes […]

Medifocus readies marketing expansion of Prolieve

Medifocus readies marketing expansion of Prolieve

July 8, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=VeDTgeap28k’]

Tweet Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or enlarged prostate, and to expand its use to include the treatment of prostatitis and prostate cancer. “Our current marketing plan for Prolieve is focused on […]

GeneNews’ IDL jv highlighted on CEO Clips

GeneNews’ IDL jv highlighted on CEO Clips

July 3, 2014 by · Leave a Comment 

Tweet James Howard-Tripp, executive chairman of GeneNews (TSX:GEN), has been featured on Business Television’s CEO Clips discussing the company’s new U.S. joint venture, Innovative Diagnostic Laboratory, or IDL. IDL’s mission is to provide a comprehensive menu of advanced blood tests that aid in early cancer detection, guide cancer treatment protocols, and monitor remission and recurrence. […]

Trillium eyeing pre-IND meeting in third quarter

Trillium eyeing pre-IND meeting in third quarter

June 17, 2014 by · Leave a Comment 

Tweet Trillium Therapeutics (TSX:TR; OTCQX:SCTPF) hopes to have a pre-IND meeting with the FDA in the second half of this year and begin clinical testing of its lead biologic cancer immunotherapy, SIRPαFc, for the treatment of acute myeloid leukaemia (AML) in the second half of 2015. “There is strong evidence that AML is sustained by leukemia […]

HCW starts France’s EDAP TMS at buy

HCW starts France’s EDAP TMS at buy

June 16, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of EDAP TMS (NASDAQ:EDP) with a “buy” rating and a price target of $6 per diluted American Depository Share (ADS). The ADS’ closed at $3.83 on Friday. EDAP, a revenue-producing French medical device company, has pioneered the use of ultrasound for therapeutic purposes, specifically in urology. Operational since 1979, […]

PHI test included in updated NCCN Guidelines

PHI test included in updated NCCN Guidelines

May 23, 2014 by · Leave a Comment 

Tweet Beckman Coulter’s Prostate Health Index (PHI), which is offered in the U.S. by GeneNews’ (TSX:GEN) Innovation Diagnostic Lab (IDL) joint venture, has been recommended by the National Comprehensive Cancer Network (NCCN) as a blood test to improve specificity for prostate cancer detection in its recently updated Clinical Practice Guidelines in Oncology (NCCN Guidelines) for […]

GeneNews’ IDL off to flying start

GeneNews’ IDL off to flying start

May 20, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics and personalized medicine. “With a successful limited scale launch of IDL in the fourth quarter of 2013, full scale-up activities began in the first […]

Alpha Cancer to test oncology game changer

Alpha Cancer to test oncology game changer

March 11, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=HJr8cGE2eVs’]

Tweet Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug candidate, ACT-901, which features a novel targeted drug delivery platform. BioTuesdays.com had an opportunity to interview the company’s founder & CEO, Dr. Igor Sherman, […]

Advaxis readies cervical cancer pivotal trial

Advaxis readies cervical cancer pivotal trial

February 25, 2014 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. “We are pleased with the encouraging results of our Phase 2 study, which supports a continuing path towards registration for our lead product candidate,” CEO Daniel O’Connor says […]

Next Page »

Email Newsletters with Constant Contact
Google+